No news items yet.



Twitter handle: @renalMRI

Check out our renal MRI resources

Coordinating research on renal MRI biomarkers for clinical practice, drug development and basic research.

The rising prevalence of Chronic Kidney Disease (CKD) poses a major public health challenge affecting >10% of the population. There exists an urgent need for better biomarkers to identify patients that are at risk of progression, or are likely to respond to (candidate) therapeutics. Magnetic Resonance Imaging (MRI) biomarkers can help to fill this gap, as they are uniquely able to track disease progression and treatment effects in the tissue itself and in a non-invasive manner (see here for a position statement by leading scientists and clinicians).


In recent years, the clinical interest in renal MRI has accelerated research and development and led to a growing excitement within an emerging multidisciplinary community of nephrologists, radiologists, surgeons, radiographers, physicists, computer scientists, pathologists and physiologists. Bi-annual international meetings have been held since 2015, and national and international consortia have been funded to work on standardization of methods, preclinical research and multi-centre clinical trials. The field has seen an increasing participation from charities and the private sector, including SME's, pharmaceutical industry and MRI scanner manufacturers. provides a central point of access to the renal MRI community and joins up all stakeholders with an aim to speed up translation into clinical practice, drug development and basic research. Check out our resources here!

Governance was created by the ongoing COST Action PARENCHIMA (CA16103) and will continue to be maintained by PARENCHIMA at until the end of the action (1 October 2021). Current planning foresees a handover of to a more informal networking of groups with an interest in MRI. A governance approach will be discussed and decided during the final PARENCHIMA meeting on the ISMRM-PARENCHIMA kidney MRI workshop in september 2021, and will be encoded in a dedicated governance section on this website.

Until the end of PARENCHIMA, ongoing activities in PARENCHIMA are organised into 5 working groups (see diagram below) and coordinated by a core team consisting of the chair and the working group leads (see below).

Working Group 1 Reproducibility & Standardisation Working Group 2 Research & Development Toolbox Working Group 5 Dissemination & Exploitation Working Group 4 Training Programs Working Group 3 Clinical studies Core Team

The core team succeeds the PARENCHIMA Core Team, which consisted of 

Steven Sourbron (Chair)

Christoffer Laustsen

Frank Zöllner

Thoralf Niendorf

Anna Caroli

Marcos Wolf